EcN Kapsül Broşür Referansları

Print
1. Cichon C et al. DNA-Microarray-based comparison of cellular responses in polarized T84 epithelial cells triggered by probiotics: E. coli Nissle 1917 (EcN) and Lactobacillus acidophilus PZ1041. Gastroenterology 2004; 126(4): A-578.
2. Zyrek AA et al. Molecular mechanisms underlying the probiotic effects of Escherichia coli Nissle 1917 involve ZO-2 and PKCz redistribution resulting in tight junction and epithelial barrier repair. Cell Microbiol 2007; 9: 804–816.
3. Ukena SN et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLOS ONE 2007; 12: e1308; 1–9.
4. Kruis W, et al. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis. 2012 Apr;27(4):467-74.
5. Möllenbrink M, Bruckschen E. Behandlung der chronischen Obstipation mit physiologischen Escherichia-coli-Bakterien. Med Klin 1994; 89:587–593
6. Sonnenborn U, Jürgen S. " The non-pathogenic Escherichia coli strain Nissle 1917 – features of a versatile probiotic. Microbial Ecology in Health and Disease. 2009; 21(3-4), 122-158.
7. Grozdanov L et al. A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002; 184: 5912–5925
8. Grozdanov L et al. Analysis of the Genome Structure of the Nonpathogenic Probiotic Escherichia coli Strain Nissle 1917 J Bacteriol. 2004; 186: 5432–5441.
9. Masjedizadeh AR, et al. Efficacy of probiotics for prevention of small intestinal bacterial overgrowth (SIBO) recurrence among patients with irritable bowel syndrome (IBS). Afro-Egyptian Journal of Infectious and Endemic Diseases. 2020;0(0):0–0.
10. Beckers M, et al. Berlin bowel bothers: Might Adolf Hitler’s gut problems have been parkinson-related? European Neurology. 2023;86(3):222–7.
11. EcN Kapsül Kitapçık
ASRAP